(Reuters) — A U.S. judge has ruled that investors who claimed that Theranos Inc. defrauded them into investing indirectly in the company by touting revolutionary blood-testing technology that never existed cannot pursue their claims as a class action.
Source: Business Insurance Magazine RSS Feed
Trackback URL: https://www.globalrec.com/2018/06/01/investors-in-blood-testing-firm-cannot-pursue-class-action-judge/trackback/
You must be logged in to post a comment.